More than 70 groups representing patients, healthcare professionals, consumers, retirees, employers, and unions launched a campaign this morning to get comprehensive Democratic drug pricing legislation signed into law by Memorial Day.
It is premature to guess how the final version
…
At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, the U.S. Health Resources and Services Administration (HRSA) said this week.
…
A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.
“First, Congress could explicitly allow the participation of
…
A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit. It is not clear whether the judge did enough to satisfy
…
The federal government on Monday accused a Tennessee health system of unlawfully paying a Memphis-area private oncology practice for patient referrals, letting the system “recoup a staggering discount in costs” through the 340B program. The 340B health system—Methodist Le Bonheur
…
The federal government, as expected, is challenging a federal district judge’s February opinion and March final orders in drug manufacturer AstraZeneca’s 340B contract pharmacy lawsuit.
The U.S. Justice Department (DOJ) announced the appeal in a one-sentence court filing on April
…
Today is the last day for hospitals that have lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork to be reinstated to the drug discount program.
A federal spending bill signed on March 15 included
U.S. Health and Human Services Secretary Xavier Becerra has extended the COVID-19 public health emergency for another 90 days, through July 15. It was due to end on Saturday, April 16.
Major hospital groups and group purchasing organizations asked Becerra
…
Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.
Astellas posted
A federal appeals court in Chicago has told a lower court in Indianapolis to issue a final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit to clear the way for the case’s next phase.
An appeals court in Philadelphia
…*Sign up for news summaries and alerts from 340B Report